These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

280 related articles for article (PubMed ID: 23138400)

  • 1. Antiepileptic effects of levetiracetam in a rodent neonatal seizure model.
    Talos DM; Chang M; Kosaras B; Fitzgerald E; Murphy A; Folkerth RD; Jensen FE
    Pediatr Res; 2013 Jan; 73(1):24-30. PubMed ID: 23138400
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The synaptic vesicle protein SV2A is the binding site for the antiepileptic drug levetiracetam.
    Lynch BA; Lambeng N; Nocka K; Kensel-Hammes P; Bajjalieh SM; Matagne A; Fuks B
    Proc Natl Acad Sci U S A; 2004 Jun; 101(26):9861-6. PubMed ID: 15210974
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Levetiracetam-induced a new seizure type in a girl with a novel SV2A gene mutation.
    Wang D; Zhou Q; Ren L; Lin Y; Gao L; Du J; Wang Y
    Clin Neurol Neurosurg; 2019 Jun; 181():64-66. PubMed ID: 31005049
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Brivaracetam, a selective high-affinity synaptic vesicle protein 2A (SV2A) ligand with preclinical evidence of high brain permeability and fast onset of action.
    Nicolas JM; Hannestad J; Holden D; Kervyn S; Nabulsi N; Tytgat D; Huang Y; Chanteux H; Staelens L; Matagne A; Mathy FX; Mercier J; Stockis A; Carson RE; Klitgaard H
    Epilepsia; 2016 Feb; 57(2):201-9. PubMed ID: 26663401
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Levetiracetam prophylaxis ameliorates seizure epileptogenesis after fluid percussion injury.
    Chen YH; Huang EY; Kuo TT; Hoffer BJ; Wu PJ; Ma HI; Tsai JJ; Chou YC; Chiang YH
    Brain Res; 2016 Jul; 1642():581-589. PubMed ID: 27106270
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of the novel antiepileptic drug levetiracetam on spontaneous recurrent seizures in the rat pilocarpine model of temporal lobe epilepsy.
    Glien M; Brandt C; Potschka H; Löscher W
    Epilepsia; 2002 Apr; 43(4):350-7. PubMed ID: 11952764
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Favorable adverse effect profile of brivaracetam vs levetiracetam in a preclinical model.
    Sanon NT; Gagné J; Wolf DC; Aboulamer S; Bosoi CM; Simard A; Messiet E; Desgent S; Carmant L
    Epilepsy Behav; 2018 Feb; 79():117-125. PubMed ID: 29287214
    [TBL] [Abstract][Full Text] [Related]  

  • 8. No major role of common SV2A variation for predisposition or levetiracetam response in epilepsy.
    Lynch JM; Tate SK; Kinirons P; Weale ME; Cavalleri GL; Depondt C; Murphy K; O'Rourke D; Doherty CP; Shianna KV; Wood NW; Sander JW; Delanty N; Goldstein DB; Sisodiya SM
    Epilepsy Res; 2009 Jan; 83(1):44-51. PubMed ID: 18977120
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The treatment of neonatal seizures: focus on Levetiracetam.
    Loiacono G; Masci M; Zaccara G; Verrotti A
    J Matern Fetal Neonatal Med; 2016; 29(1):69-74. PubMed ID: 25385270
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Retrospective analysis of the efficacy and tolerability of levetiracetam in patients with metastatic brain tumors.
    Newton HB; Dalton J; Goldlust S; Pearl D
    J Neurooncol; 2007 Sep; 84(3):293-6. PubMed ID: 17431542
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Profile of anticonvulsant action of levetiracetam, tiagabine and phenobarbital against seizures evoked by DMCM (methyl-6,7-dimethoxy-4-ethyl-β-carboline-3-carboxylate) in neonatal rats.
    Kulick CV; Gutherz SB; Beck VC; Medvedeva N; Soper C; Forcelli PA
    Eur J Pharmacol; 2014 Nov; 743():63-8. PubMed ID: 25246016
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evidence for a differential interaction of brivaracetam and levetiracetam with the synaptic vesicle 2A protein.
    Wood MD; Gillard M
    Epilepsia; 2017 Feb; 58(2):255-262. PubMed ID: 28012162
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Omega 3 polyunsaturated fatty acids enhance the protective effect of levetiracetam against seizures, cognitive impairment and hippocampal oxidative DNA damage in young kindled rats.
    Abdel-Wahab BA; Shaikh IA; Khateeb MM; Habeeb SM
    Pharmacol Biochem Behav; 2015 Aug; 135():105-13. PubMed ID: 26044965
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A Systematic Review of the Efficacy of Levetiracetam in Neonatal Seizures.
    McHugh DC; Lancaster S; Manganas LN
    Neuropediatrics; 2018 Feb; 49(1):12-17. PubMed ID: 29179233
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Proepileptic phenotype of SV2A-deficient mice is associated with reduced anticonvulsant efficacy of levetiracetam.
    Kaminski RM; Gillard M; Leclercq K; Hanon E; Lorent G; Dassesse D; Matagne A; Klitgaard H
    Epilepsia; 2009 Jul; 50(7):1729-40. PubMed ID: 19486357
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Levetiracetam Prevents Neurophysiological Changes and Preserves Cognitive Function in the Human Immunodeficiency Virus (HIV)-1 Transactivator of Transcription Transgenic Mouse Model of HIV-Associated Neurocognitive Disorder.
    Ewens AN; Pilski A; Hastings SD; Krook-Magnuson C; Graves SM; Krook-Magnuson E; Thayer SA
    J Pharmacol Exp Ther; 2024 Sep; 391(1):104-118. PubMed ID: 39060163
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evidence for a unique profile of levetiracetam in rodent models of seizures and epilepsy.
    Klitgaard H; Matagne A; Gobert J; Wülfert E
    Eur J Pharmacol; 1998 Jul; 353(2-3):191-206. PubMed ID: 9726649
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Brivaracetam: Rationale for discovery and preclinical profile of a selective SV2A ligand for epilepsy treatment.
    Klitgaard H; Matagne A; Nicolas JM; Gillard M; Lamberty Y; De Ryck M; Kaminski RM; Leclercq K; Niespodziany I; Wolff C; Wood M; Hannestad J; Kervyn S; Kenda B
    Epilepsia; 2016 Apr; 57(4):538-48. PubMed ID: 26920914
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Separation of antiepileptogenic and antiseizure effects of levetiracetam in the spontaneously epileptic rat (SER).
    Yan HD; Ji-qun C; Ishihara K; Nagayama T; Serikawa T; Sasa M
    Epilepsia; 2005 Aug; 46(8):1170-7. PubMed ID: 16060925
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacodynamic and pharmacokinetic characterization of interactions between levetiracetam and numerous antiepileptic drugs in the mouse maximal electroshock seizure model: an isobolographic analysis.
    Luszczki JJ; Andres MM; Czuczwar P; Cioczek-Czuczwar A; Ratnaraj N; Patsalos PN; Czuczwar SJ
    Epilepsia; 2006 Jan; 47(1):10-20. PubMed ID: 16417526
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.